<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04906473</url>
  </required_header>
  <id_info>
    <org_study_id>KPC/KY100001/C101</org_study_id>
    <nct_id>NCT04906473</nct_id>
  </id_info>
  <brief_title>Safety,Tolerability, Pharmacokinetic,Pharmacodynamics and Efficacy of KY100001 in Patients With Advanced Solid Tumors</brief_title>
  <official_title>A Phase Ⅰ Clinical Study of Single-arm, Open, Single/Multiple Dose Escalation and Dose Extension to Assess the Safety, Tolerability, Pharmacokinetic, Pharmacodynamics and Efficacy of KY100001 in Patients With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kunming Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kunming Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      to assess the safety,tolerability, pharmacokinetic,pharmacodynamics and efficacy of KY100001&#xD;
      in patients with advanced solid tumors&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 31, 2021</start_date>
  <completion_date type="Anticipated">October 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Single-arm, open, single/multiple dose escalation (100mg/d, 200mg/d, 350mg/d, 550mg/d, 750mg/d) and dose Extension</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of subjects with abnormal vital signs</measure>
    <time_frame>through study completion, an average of 12 weeks</time_frame>
    <description>To evaluate the safety of KY100001 in subjects with advanced solid cancer in terms of abnormal vital signs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with abnormal physical examination</measure>
    <time_frame>through study completion, an average of 12 weeks</time_frame>
    <description>To evaluate the safety of KY100001 in subjects with advanced solid cancer in terms of abnormal physical examination</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with abnormal laboratory examination</measure>
    <time_frame>through study completion, an average of 12 weeks</time_frame>
    <description>To evaluate the safety of KY100001 in subjects with advanced solid cancer in terms of abnormal laboratory examination</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with abnormal electrocardiogram</measure>
    <time_frame>through study completion, an average of 12 weeks</time_frame>
    <description>To evaluate the safety of KY100001 in subjects with advanced solid cancer in terms of abnormal electrocardiogram</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in ECOG score</measure>
    <time_frame>through study completion, an average of 12 weeks</time_frame>
    <description>To evaluate the safety of KY100001 in subjects with advanced solid cancer in terms of ECOG score</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of KY100001: Cmax</measure>
    <time_frame>4 weeks</time_frame>
    <description>Pharacokinetic evaluation in terms of Cmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of KY100001: Tmax</measure>
    <time_frame>4 weeks</time_frame>
    <description>Pharacokinetic evaluation in terms of Tmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of KY100001: T1/2</measure>
    <time_frame>4 weeks</time_frame>
    <description>Pharacokinetic evaluation in terms of T1/2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of KY100001: AUC</measure>
    <time_frame>4 weeks</time_frame>
    <description>Pharacokinetic evaluation in terms of AUC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The relationship between 2-hydroxyglutaric acid (2-HG) level and curative effect</measure>
    <time_frame>4 weeks</time_frame>
    <description>biomarker evaluation in terms of 2-hydroxyglutaric acid (2-HG)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>through study completion, an average of 12 weeks</time_frame>
    <description>effectiveness evaluation in terms of Objective Response Rate (ORR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>through study completion, an average of 12 weeks</time_frame>
    <description>effectiveness evaluation in terms of Overall Survival (OS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS)</measure>
    <time_frame>through study completion, an average of 12 weeks</time_frame>
    <description>effectiveness evaluation in terms of Progression-Free Survival (PFS)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">109</enrollment>
  <condition>Advanced Solid Tumor</condition>
  <arm_group>
    <arm_group_label>KY100001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>KY100001; Tablet; Oral route; Dose escalation and dose extension</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KY100001</intervention_name>
    <description>KY100001; Tablet; Oral route; Dose escalation and dose extension</description>
    <arm_group_label>KY100001</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1) Participate in the study voluntarily and sign the informed consent;&#xD;
&#xD;
          -  2) 18≤ age ≤75 years old, gender is not limited;&#xD;
&#xD;
          -  3) Dose escalation stage: patients with advanced solid tumor proven histologically or&#xD;
             cytologically without standard treatment regimen, or with recurrence or progression&#xD;
             after standard treatment, WHO are ineffective or intolerant to standard treatment&#xD;
             regimen (for patients with glioma, WHO grade II, III and IV can be included);&#xD;
&#xD;
          -  4) Dose expansion phase IDH1 mutation positivity in part A/B:&#xD;
             Non-cholangiocarcinoma/glioma: Any of the following conditions are allowed: A)&#xD;
             Subjects provide genetic test report to prove IDH1 mutation positivity (NGS or&#xD;
             qPCR);B) Subjects who voluntarily undergo tumor biopsy and/or blood sample collection&#xD;
             for genetic testing and the test results are positive;C) Subjects can provide the last&#xD;
             FFPE sample or pathological slides (at least 10 consecutive white slides) and&#xD;
             voluntarily accept blood sample collection for genetic testing, and the test result is&#xD;
             positive;Patients with cholangiocarcinoma/glioma: Any of the following conditions are&#xD;
             allowed: a) Subjects who provide prior genetic testing report demonstrating IDH1&#xD;
             mutation positivity (NGS or qPCR);B) Subjects can provide the most recent FFPE sample&#xD;
             or pathological section (at least 10 consecutive white films) or tissue biopsy sample&#xD;
             (patients with cholangiocarcinoma should also voluntarily accept blood sample&#xD;
             collection) for genetic testing, and the test result is positive;&#xD;
&#xD;
          -  5) Dose Expansion Phase A: Patients with advanced solid tumors with IDH1 gene mutation&#xD;
             positive, proven histologically or cytologically, without standard treatment regimens,&#xD;
             or relapse or progression after standard treatment, ineffective or intolerant to&#xD;
             standard treatment regimens;&#xD;
&#xD;
          -  6) Dose expansion phase B: patients with cholangiocarcinoma/high-grade glioma (WHO&#xD;
             grade III &amp;IV) with IDH1 gene mutation positive, histologically or cytologically&#xD;
             proven, WHO do not have a standard treatment regimen, or WHO relapse or progress after&#xD;
             standard treatment, are ineffective or intolerant to the standard treatment&#xD;
             regimen.Cohort 1: a) Histologically proven stage II-IV cholangiocarcinoma with IDH1&#xD;
             gene mutation positive, not eligible for radical resection, transplantation, or&#xD;
             ablation;B) disease progression after treatment with a fluorouracil or gemcitabine&#xD;
             basal regimen;C) at least one measurable lesion that has not previously undergone&#xD;
             radiotherapy, chemoembolization, radioembolization or other local ablation&#xD;
             procedures;Cohort 2: a) high-grade gliomas with IDH1 gene mutation positivity (WHO&#xD;
             grade III &amp;IV);B) The number of disease progression ≤2 times during screening;C) At&#xD;
             least one previous CEMRI + perfusion MRI;D) at least one measurable lesion ≥1cm&#xD;
             (according to RANO criteria);&#xD;
&#xD;
          -  7) At least one measurable lesion (non-glioma according to RECIST v1.1 criteria;Brain&#xD;
             glioma according to RANO criteria);&#xD;
&#xD;
          -  8) Dose increasing stage: non-glioma patients (Eastern Cooperative Cancer Group (ECOG)&#xD;
             score: 0-2) glioma patients (KPS score ≥50);Dose extension stage: non-glioma patients&#xD;
             (ECOG score: 0-1 points);Glioma patients (KPS score ≥50);&#xD;
&#xD;
          -  9) Expected survival ≥3 months;&#xD;
&#xD;
          -  10) Within 7 days prior to the administration of the study drug, laboratory tests have&#xD;
             met the following criteria.Absolute neutrophils count (ANC) ≥ 1.5×109 /L;Platelet&#xD;
             count ≥ 80×109 /L;Hemoglobin ≥ 90 g/L;Serum creatinine ≤ 1.5x upper normal range (ULN)&#xD;
             or creatinine clearance rate (CRCL) ≥ 60mL/min (estimated according to Cockcroft-Gault&#xD;
             formula);Total bilirubin ≤ 1.5 X ULN or ≤ 2 X ULN (for patients with liver&#xD;
             metastasis);AST and ALT≤ 2.5 X ULN or ≤ 5 X ULN (for patients with liver&#xD;
             metastasis);Alkaline phosphatase ≤ 2.5 X ULN or ≤ 5 X ULN (for patients with bone&#xD;
             metastases and/or suspected disease related liver or bile duct&#xD;
             involvement);International Normalized Ratio or Prothrombin Time≤ 1.3x ULN;Partial&#xD;
             activated thromboplastin time (APTT) ≤ 1.5 X ULN;&#xD;
&#xD;
          -  11) Fertile men and women of reproductive age must agree to use reliable contraception&#xD;
             from the time of signing the informed consent until 180 days after the last dose of&#xD;
             the study drug.Women of childbearing age include pre-menopausal women and women within&#xD;
             2 years after menopause.Blood pregnancy test results of women of reproductive age must&#xD;
             be negative no more than 7 days before the first study drug administration.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1) Allergic constitution, or previous history of severe allergy, or known allergy to&#xD;
             the active ingredients and excipients of the study drug;&#xD;
&#xD;
          -  2) Surgical therapy, chemotherapy, radiation therapy, immunotherapy, molecular&#xD;
             targeted therapy, or any other anti-tumor therapy within 4 weeks prior to the first&#xD;
             administration of the study drug;&#xD;
&#xD;
          -  3) Non-glioma patients: untreated patients with brain metastases who have symptoms or&#xD;
             require treatment to control their symptoms;Or had used any radiation, surgical or&#xD;
             other treatment, including treatment to control symptoms, within 2 months prior to the&#xD;
             first administration of the study drug;Patients with glioma: Patients who received an&#xD;
             unsteady dose of dexamethasone exceeding the equivalent dose of 5mg/ day 5 days before&#xD;
             MRI screening;&#xD;
&#xD;
          -  4) Had any of the following heart conditions: a) Had grade III-IV heart failure&#xD;
             according to the New York Heart Association's cardiac function rating within 28 days&#xD;
             prior to the first administration of the study drug, or had left ventricular ejection&#xD;
             fraction (LVEF) ≤50% in Echo within 7 days prior to the first administration of the&#xD;
             study drug;B) The history of myocardial infarction in the previous 6 months was&#xD;
             screened;C) known unstable angina;D) known severe or uncontrolled ventricular&#xD;
             arrhythmias;E) Screening-phase Fridericia calibrated QT interval (QTCF) ≥450 ms&#xD;
             (male), ≥470 ms (female), or other factors that increase the risk of prolonged QTC or&#xD;
             arrhythmic events (such as heart failure, low potassium, and a family history of long&#xD;
             QT syndrome);F) In the screening period, there was hypertension that was still poorly&#xD;
             controlled after drug treatment (systolic blood pressure ≥160mmHg, diastolic blood&#xD;
             pressure ≥ 100mmHg);&#xD;
&#xD;
          -  5) Difficulty in swallowing or suffering from gastrointestinal diseases or other&#xD;
             malabsorption conditions that affect drug absorption, such as intestinal obstruction,&#xD;
             Crohn's disease, ulcerative colitis, short bowel syndrome, gastric emptydisturbance;Or&#xD;
             severe gastrointestinal related toxicity that does not recover below grade 2 prior to&#xD;
             initial administration;Or clinically significant or acute gastrointestinal disease;&#xD;
&#xD;
          -  6) Previous interstitial pulmonary disease, pulmonary fibrosis, drug-induced&#xD;
             interstitial pulmonary disease, or radiation pneumonia disease or history;&#xD;
&#xD;
          -  7) Evidence of severe or uncontrolled liver or kidney disease;&#xD;
&#xD;
          -  8) Hepatitis B virus infection (HBcAb positive and HBV DNA lower than the detection&#xD;
             limit could be included);Or people infected with hepatitis C virus (defined as HCV&#xD;
             antibody positive);Or persons infected with the human immunodeficiency virus (defined&#xD;
             as HIV-positive);&#xD;
&#xD;
          -  9) Active severe infection requiring anti-infective treatment or unexplained fever&#xD;
             over 38℃ within 28 days prior to the first administration of the study drug;&#xD;
&#xD;
          -  10) Prior to the initial administration of the study drug, any toxicity from prior&#xD;
             antitumor therapy had not returned to CTCAE 5.0 grade ≤1 (except for grade 2 alopecia,&#xD;
             which could be included in secondary peripheral neuropathy determined by the&#xD;
             investigator and medical examiner to be primary residual toxicity or stable from prior&#xD;
             chemotherapy);&#xD;
&#xD;
          -  11) Participated in other clinical trials within 28 days prior to the first&#xD;
             administration of the study drug;&#xD;
&#xD;
          -  12) Use of CYP2C8, CYP3A strong inhibitor or inducer within 2 weeks before the first&#xD;
             administration of the drug in this study;&#xD;
&#xD;
          -  13) Use of drugs known to extend the Qt /QTc interval within 2 weeks before the first&#xD;
             administration of the study drug;&#xD;
&#xD;
          -  14) Pregnant or lactating women;&#xD;
&#xD;
          -  15) The investigator believes that there is any abnormal clinical or laboratory&#xD;
             examination or other reasons and he/she is not suitable to participate in the clinical&#xD;
             investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lin Shen, prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Cancer Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Qiang Zhang, bachelor</last_name>
    <phone>0871-68319868-3052</phone>
    <email>qiang.zhang@kpc.com.cn</email>
  </overall_contact>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 18, 2021</study_first_submitted>
  <study_first_submitted_qc>May 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 28, 2021</study_first_posted>
  <last_update_submitted>May 26, 2021</last_update_submitted>
  <last_update_submitted_qc>May 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>biliary duct cancer</keyword>
  <keyword>glioma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

